 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...56789101112131415...4950» |
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Final analysis of the Phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer (Stars at Night Ballrooms 3&4) - Oct 28, 2022 - Abstract #SABCS2022SABCS_2008;
P2, P3
PEONY adds to the totality of data showing the benefit of the P+H+D regimen in HER2-positive EBC. Long-term efficacy data
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study (Hall 1) - Oct 28, 2022 - Abstract #SABCS2022SABCS_1886;
P2
This was mainly driven by the patients without a g/tBRCA mutation. In patients with a g/t BRCA mutation no difference between olaparib and carboplatinum was seen.
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg., dexrazoxane / Generic mfg.
Journal: Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients. (Pubmed Central) - Oct 28, 2022
We discuss some of the pharmacological strategies proposed to mitigate anthracycline-associated cardiotoxicity as well as prevention strategies to reduce the burden of coexisting cardiovascular risk factors. We highlight methods of early detection of patient cohorts who are at increased risk of developing anthracycline-associated cardiotoxicity and identify potential avenues for further research.
- | epirubicin / Generic mfg.
Journal: An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis. (Pubmed Central) - Oct 26, 2022
A targeting ligand (SA-CH), composed of SA and cholesterol, was synthesized and modified on the surface of epirubicin (EPI)-loaded liposomes (EPI-SL) as an effective targeting delivery system...Our study demonstrated the significant potential of SA-modified liposomes in antitumor metastasis. Schematic diagram of the role of SA-CH modified EPI-loaded liposomes in the model of breast cancer metastasis.
- | epirubicin / Generic mfg.
Preclinical, Journal: IGT mediated Nanog siRNA delivery in prostate cancer cells improves chemosensitization of Epirubicin in vitro. (Pubmed Central) - Oct 25, 2022
Nanog downregulation in prostate cancer cell line DU145 in serum containing media led to suppression of associated proteins such as KLF4, FAK and cMyc and also enhanced the chemosensitivity of Epirubicin, an anthracycline based drug, in DU145 cells by associated MDR-1 downregulation in vitro. These results show that IGT is a promising candidate for siRNA delivery and its conjugation with stable siRNAs could enhance the chemotherapeutic efficiency of siRNAs alone and in combination with small molecule-based drugs.
- | 5-fluorouracil / Generic mfg.
Journal: Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy. (Pubmed Central) - Oct 24, 2022
These results show that IGT is a promising candidate for siRNA delivery and its conjugation with stable siRNAs could enhance the chemotherapeutic efficiency of siRNAs alone and in combination with small molecule-based drugs. Anthracycline-based regimen caused comparatively higher peripheral inflammation, which could be the reason for more decline in cognition in anthracycline-receiving patients than non-anthracycline group.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Impact of body mass index on survival in women receiving chemotherapy for early breast cancer. (Pubmed Central) - Oct 22, 2022
Our large population-based retrospective cohort analysis of EBC patients receiving adjuvant anthracycline-taxane chemotherapy found no significant impact of BMI on OS. Further investigation is warranted to confirm these findings in prospective patient cohorts.
- | carboplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach. (Pubmed Central) - Oct 21, 2022
Finally, drug-likeness, ADME, and toxicity prediction were fulfilled in this investigation, and it is noted that all the derivatives were highly soluble in a water medium, whereas they were totally free from AMES toxicity, hepatotoxicity, and skin sensitization, excluding only ligands 1 and 7. Thus, we proposed that the natural myricetin derivatives could be a better inhibitor for treating breast and lung cancer.
- mitomycin / Generic mfg., epirubicin / Generic mfg.
Treatment adherence of patients with bladder cancer undergoing endovesical instillations 2 years post-COVID-19 pandemic () - Oct 21, 2022 - Abstract #PROSCABLADDR2022PROSCA_BLADDR_164;
In conclusion, the discontinuation rate due to fear of immunosuppression in our cohort was low, mostly observed in patients on endovesical BCG instillations. Special consideration should be given to patients with certain social or clinical characteristics, such as unemployment and underlying pulmonary diseases.
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant pembrolizumab+chemotherapy vs placebo+chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_173;
P3
Schmid P, et al. N Engl J Med 2022; 386:556-67.
- | Trial completion date, Metastases: Tumorspheres Colrec: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2022
P2, N=90, Active, not recruiting, Sponsor: Vejle Hospital
N Engl J Med 2022; 386:556-67. Trial completion date: Aug 2022 --> Dec 2022
- 5-fluorouracil / Generic mfg.
DOSE-DENSE CHEMOTHERAPY IN ADJUVANT TREATMENT OF PATIENTS WITH EARLY-STAGE BREAST CANCER: ENDOF-STUDY RESULTS FROM A RANDOMISED, PHASE 3 TRIAL OF THE GRUPPO ITALIANO MAMMELLA (GIM) (Titian Room 3) - Oct 19, 2022 - Abstract #AIOM2022AIOM_52;
The final analysis confirmed an improved DFS and OS with the use of DD as compared with the standard schedule. The DD should be considered the standard adjuvant chemotherapy schedule for node-posi- tive breast cancer patients.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, epirubicin / Generic mfg.
Clinical: Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial https://t.co/gGjAczICC2 @CCR_AACR novel approach to Catequentinib/anlotinib for sarcoma (Twitter) - Oct 17, 2022
- | New P1/2 trial: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Oct 17, 2022
P1/2, N=716, Not yet recruiting, Sponsor: Fudan University
- | Journal: Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. (Pubmed Central) - Oct 16, 2022
The DD should be considered the standard adjuvant chemotherapy schedule for node-posi- tive breast cancer patients. mFLOT is associated with improved resection rates and survival in comparison to EOX as perioperative therapy in gastric adenocarcinomas in this large real-world cohort, with manageable increase in clinically relevant toxicities such as grade 3 and grade 4 febrile neutropenia and neutropenia.
- ||| Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Journal, Adverse events: Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells. (Pubmed Central) - Oct 15, 2022
The washing of the cell surface following incubation with diluted Proemend containing FAP and Tween-80 eliminated the synergic cytotoxicity of EPI applied thereafter. These results indicated that washing of the infusion-site vascular tissue following intravenous Proemend administration via intravenous tube flushing with an efficient amount of saline may reduce the infusion-site adverse events, which are caused by the combined use of FAP and EPI.
- | Stivarga (regorafenib) / Bayer
Journal: TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. (Pubmed Central) - Oct 14, 2022
TOP2A inhibition by doxorubicin or epirubicin synergized with regorafenib to suppress the growth of sorafenib-resistant HCC tumors that possessed the sorafenib-resistant features both in vitro and in vivo. Thus, targeting TOP2A may be a promising therapeutic strategy to alleviate resistance to regorafenib and thus improving the efficacy of HCC treatment.
- | epirubicin / Generic mfg.
Journal: Delivery of DNA octahedra enhanced by focused ultrasound with microbubbles for glioma therapy. (Pubmed Central) - Oct 14, 2022
We investigated the delivery outcome of pH-responsive DNA octahedra loading Epirubicin (Epr@DNA-Octa) via FUS/MB and its therapeutic efficiency in a mouse model bearing intracranial glioma xenograft...The beneficial effect on survival was most significant in the Epr@DNA-Octa + FUS/MB group, with a 50% increase in median survival and a 73% increase in the maximum survival compared to control animals. Our work demonstrates the potential viability of FUS/MB as an alternative strategy for glioma delivery of anticancer drugs using DNA nanostructures as the drug delivery platform for brain cancer therapy.
- | Cytovene (ganciclovir) / Roche
Journal: Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels. (Pubmed Central) - Oct 14, 2022
Accuracies ranged between 117% and 83% at the LOQ, intermediate and upper LOQ concentrations, with relative standard deviations (RSD) inferior to 8%, for all the antineoplastic drugs. Finally, the UHPLC-MS/MS method was successfully applied to the analysis of surface samples to evaluate the chemical contamination by these highly toxic compounds in a chemotherapy preparation unit in a hospital pharmacy with the purpose of monitoring the exposure of health care professionals.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial. (Pubmed Central) - Oct 14, 2022
Finally, the UHPLC-MS/MS method was successfully applied to the analysis of surface samples to evaluate the chemical contamination by these highly toxic compounds in a chemotherapy preparation unit in a hospital pharmacy with the purpose of monitoring the exposure of health care professionals. The combination of anlotinib and epirubicin followed by anlotinib maintenance demonstrated promising efficacy with a favorable safety profile.
- | mitomycin / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Review, Journal: Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. (Pubmed Central) - Oct 13, 2022
From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0.05) with pooled Risk Ratio were 0.69 and pooled heterogeneity (I) were 26.6%. This meta-analysis study showed that combination therapy of intravesical chemotherapy after TURB is superior to TURB alone in showing the recurrence rate of NMIBC.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era. (Pubmed Central) - Oct 12, 2022
This meta-analysis study showed that combination therapy of intravesical chemotherapy after TURB is superior to TURB alone in showing the recurrence rate of NMIBC. Patients with FL/DLBCL showed inferior treatment response and survival than those with pure FL and had a lower CR rate and PFS, but similar OS to those with DLBCL in the rituximab era.
- | 5-fluorouracil / Generic mfg.
Journal: Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy. (Pubmed Central) - Oct 12, 2022
Patients with FL/DLBCL showed inferior treatment response and survival than those with pure FL and had a lower CR rate and PFS, but similar OS to those with DLBCL in the rituximab era. Baseline TL is not associated with chemotherapy-related toxicity nor long-term outcome in BC patients.
- | Epidaza (chidamide) / Chipscreen
New P2 trial, Combination therapy: Phase ? Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (clinicaltrials.gov) - Oct 10, 2022
P2, N=47, Recruiting, Sponsor: Sun Yat-sen University
- Tecentriq (atezolizumab) / Roche
Comparison of a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono (Stars at Night Ballroom 1&2) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1832;
The addition of an ICI to state of the art neoadjuvant chemotherapy has recently been established as a new standard of care in TNBC. NeoMono has the potential to answer the question if the beneficial effect of the ICI can be increased by a chemotherapy free ICI monotherapy window prior to a combination with neoadjuvant chemotherapy.
- Imfinzi (durvalumab) / AstraZeneca
Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients (Hemisfair Ballroom 1&2) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1824;
The flow cytometry-based immunomonitoring of the clinical trial identified different immune-relevant biomarkers at recruitment as well as during treatment that predict clinical response to durvalumab. After validation of this data in an independent patient cohort, these markers could be implemented for an improved patient stratification to immunotherapy.
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study (Stars at Night Ballrooms 1&2) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1772;
P3
An EFS benefit was observed in patients who received pembro with either concurrent or sequential adjuvant RT. The addition of pembro to adjuvant RT was generally well tolerated.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1756;
The addition of pembro to adjuvant RT was generally well tolerated. Patients with stage II-III HER2-positive breast cancer show favorable clinical and pathological response to this ECP-THP neoadjuvant regimen, with an acceptable safety profile.
- Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Assessing Response to neoadjuvant Taxotere and TrAstuzumab in Nigerian women with HER2-positive breast cancer (ARETTA) (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1754;
P2
Those with incomplete clinical response by breast ultrasound volume measurements receive 3 additional cycles of chemotherapy; cyclophosphamide 600mg/m2, epirubicin 90mg/m2 and 5-fluorouracil 600mg/m2 every 3 weeks before re-evaluation for surgery...Secondary objectives are to evaluate invasive disease-free survival (iDFS), the pattern of response and mechanisms of resistance to treatment based on genomic markers, the pharmacokinetics of Herceptin SC, quality of life, and adverse event rates, including cardiac toxicity...More protocol details can be found at ClinicalTRial.gov NCT03879577 and JCO Glob Oncol2020 doi: 10.1200/GO.20.00043 Progress: The study has met its primary endpoint and will be closed to accrual by the time of the meeting. Results will be submitting as Late Breaking before the meeting
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: an open-label, single-arm phase II study (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1746;
Results will be submitting as Late Breaking before the meeting Nab-paclitaxel followed by dose-dense EC as NAC demonstrates promising anti-tumor activity and acceptable tolerability for patients with TNBC.
- Herceptin (trastuzumab) / Roche
Monitoring for cardiotoxicity in early breast cancer: an Australian experience (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1343;
This has led to the development of new clinical guidelines to screen and manage high risk breast cancer patients receiving cardiotoxic therapies. This has empowered patients, care coordinators and physicians to proactively manage cardiac risks from therapy and we hope these institutional guidelines will be adopted nationally.
- delanzomib (CEP-18770) / Teva, Ninlaro (ixazomib) / Takeda, Aqupla (nedaplatin) / Simcere
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1173;
In summary, some proteasome inhibitors (e.g. bortezomib) had a substantial impact on TNBC cell survival. These findings indicate that proteasome inhibitors, together with other forms of chemotherapy, may be further explored as a novel complement treatment for TNBC.
- ClinicalomicsDB - Bridging the gap between clinical omics data and machine learning (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_610;
Therapy shows various cytotoxic and/or targeted treatments utilized in a clinical trial. The database will be continuously expanded to include additional trials for breast cancer and other cancer types.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The efficacy of Anlotinib combined with TEC in neo-adjuvant treatment for triple-negative breast cancer and the value of multi-point core needle biopsy in prediction of pathologic complete remission: A retrospective analysis (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_514;
It is safe, reliable, feasible and accurate to evaluate the efficacy of neo-adjuvant therapy and to predict pathological complete response by multi-point core needle biopsy. It means that the clinical evaluation of neo-adjuvant therapy can transition from imaging evaluation to pathological evaluation, which is helpful for the choice of surgical methods.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Adjuvant and neoadjuvant chemotherapy for treatment of early and locally advanced breast cancer in the elderly population at a UK tertiary cancer centre (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_314;
Epirubicin/paclitaxel/cyclophosphamide/trastuzumab/pertuzumab (35.0%) and ECT (32.0%) were the most frequent chemotherapy regimens. This study shows that a large proportion of older patients with breast cancer require changes to their initial chemotherapy dose intensity, with neutropenia and peripheral neuropathy being significant toxicities in neoadjuvant and adjuvant treatment respectively.
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study (Hall 3) - Oct 10, 2022 - Abstract #SABCS2022SABCS_171;
P2
This was mainly driven by the patients without a g/tBRCA mutation. In patients with a g/t BRCA mutation no difference between olaparib and carboplatinum was seen.
- Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial (Hall 3) - Oct 10, 2022 - Abstract #SABCS2022SABCS_170;
NACT in control arm included paclitaxel 100 mg/m2 once per week for 8 weeks followed by doxorubicin (60 mg/m2) or epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) once every 21 days for 4 cycles while in experimental arm carboplatin (area-under-curve 2) was added once per week for 8 weeks with paclitaxel. This study, to our knowledge the largest reported trial of neoadjuvant platinum in TNBC thus far, suggests that addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy results in substantial and clinically meaningful improvement in disease-free and overall survival in young patients with TNBC and should be the standard of care in these patients.
- | docetaxel / Generic mfg.
Preclinical, Journal: β-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines. (Pubmed Central) - Oct 10, 2022
The non-correlation of the IC values of DTX between the 2D and 3D culture methods does not appear to be due to the changes in β-tubulin isoforms. Morphology in the 3D culture method may play some role in drug sensitivity.
- ifosfamide / Generic mfg., mesna / Generic mfg., epirubicin / Generic mfg.
Successful Multimodal Treatment of an Advanced Case of Axillary Synovial Sarcoma (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_978;
She is due to for surveillance scans and TSH monitoring every 3-6 months for two years. A breast MRI, approximately eight years after she received radiation is also planned for breast cancer screening.
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P2 trial: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (clinicaltrials.gov) - Oct 6, 2022
P2, N=120, Not yet recruiting, Sponsor: SOLTI Breast Cancer Research Group
- || Review, Journal: The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside. (Pubmed Central) - Oct 4, 2022
However, as mitochondria are susceptible to damage, the MQC system, including mitochondrial dynamics (fusion/fission), mitophagy, mitochondrial biogenesis, and mitochondrial protein quality control, appears to be crucial in maintaining mitochondrial homeostasis. In this review, we summarize current evidence on the role of MQC in the pathogenesis of AIC and highlight the therapeutic potential of restoring the cardiomyocyte MQC system in the prevention and intervention of AIC.
- Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting (Hall 404) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_347;
P3
During the post-treatment follow up period, AEs were reported for 64 (27.4%) and 72 (29.8%) patients in the HD201 and the referent trastuzumab groups respectively and no serious event was related to study treatment. Conclusions This final analysis of the TROIKA trial further confirms the comparable efficacy and safety of HD201 and referent trastuzumab.
- || doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Review, Journal: Interplay between PI3K/AKT pathway and heart disorders. (Pubmed Central) - Sep 30, 2022
Moreover, PI3K/AKT pathway participates in the process of myocardial injury induced by a number of substances such as HO, Mercury, lipopolysaccharides, adriamycin, doxorubicin and epirubicin. In this review, we describe the contribution of this pathway in the pathoetiology of myocardial ischemia/reperfusion injury and myocardial infarction, heart failure, cardiac hypertrophy, cardiomyopathy and toxins-induced cardiac injury.
- | Trial completion, Trial primary completion date: NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) (clinicaltrials.gov) - Sep 30, 2022
P3, N=377, Completed, Sponsor: Cancer Trials Ireland
In this review, we describe the contribution of this pathway in the pathoetiology of myocardial ischemia/reperfusion injury and myocardial infarction, heart failure, cardiac hypertrophy, cardiomyopathy and toxins-induced cardiac injury. Active, not recruiting --> Completed | Trial primary completion date: Mar 2023 --> Aug 2022
- || Vectibix (panitumumab) / Amgen
Trial completion: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Sep 30, 2022
P2, N=47, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2023 --> Aug 2022 Active, not recruiting --> Completed
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Review, Journal: A Case of Stage Ⅳ Triple Negative Breast Cancer(TNBC)in Which S-1 Was Successful against Armor-Like Infiltration of the Chest Wall (Pubmed Central) - Sep 30, 2022
Epirubicin plus cyclophosphamide therapy(EC therapy)plus weekly paclitaxel therapy(weekly PTX)was started for the unresectable advanced breast cancer, but infiltration of an armor-like tumor was observed in the chest wall...However, we did not control the disease, and the patient died. We report about the positioning of S-1 with regard to TNBC, including a literature review.
- | epirubicin / Generic mfg.
Journal: A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. (Pubmed Central) - Sep 30, 2022
Herein, a self-amplified biomimetic nanosystem, mEHGZ, was constructed by encapsulation of epirubicin (EPI), glucose oxidase (Gox) and hemin in ZIF-8 nanoparticles and coating of the nanoparticles with calreticulin (CRT) over-expressed tumor cell membrane...Treatment with the nanosystem in combination with anti-PD-L1 antibody results in distinctive inhibition of tumor growth and lung metastasis, supporting that a potent ICD effect can significantly boost the therapeutic efficacy of the anti-PD-L1 antibody. This self-amplified biomimetic nanoplatform offers a promising means of raising the response rate of immune checkpoint inhibitors.
- | cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography. (Pubmed Central) - Sep 29, 2022
This self-amplified biomimetic nanoplatform offers a promising means of raising the response rate of immune checkpoint inhibitors. Strain ultrasonic elastography may be used to evaluate the effects of preoperative NAC in patients with breast cancer.
- | epirubicin / Generic mfg.
Journal: Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α. (Pubmed Central) - Sep 29, 2022
Meanwhile, animal models showed that Tan I not only improved the anti-tumor effect of EADM, but also reduced the drug reactions of EADM-induced weight loss. Our results suggested that Tan I could effectively improve the anti-tumor effect of EADM, and synergize EADM to reverse HIF-1α mediated resistance via targeting PI3K/AKT/HIF-1α signaling pathway.
- | epirubicin / Generic mfg.
Journal: Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. (Pubmed Central) - Sep 29, 2022
This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads (DEB-TACE) loaded with epirubicin or selective conventional TACE (cTACE) with epirubicin-ethiodized oil might be more effective for obtaining complete response(CR) in patients with HCC...However, the frequency of postembolization syndrome was also significantly higher in the cTACE group than in the DEB-TACE group. Thus, to achieve CR, cTACE may be selected over DEB-TACE in patients who can be expected to tolerate postembolization syndrome.